13741-90-7

Basic information

• Product Name: 2,4,6-triaminoquinazoline
• Synonyms: Quinazoline-2,4,6-triaMine
• CAS NO: 13741-90-7
• Molecular Formula: C₈H₉N₅
• Molecular Weight: 175.19
• Mol File: 13741-90-7.mol
• Article Data: 14

Chemical Properties

• Boiling Point: 560.5°C at 760 mmHg
• Flash Point: 327.2°C
• Appearance: /
• Density: 1.499g/cm³
• Vapor Pressure: 1.37E-12mmHg at 25°C
• Refractive Index: 1.868
• CAS DataBase Reference: 2,4,6-triaminoquinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4,6-triaminoquinazoline(13741-90-7)
• EPA Substance Registry System: 2,4,6-triaminoquinazoline(13741-90-7)

Safety Data

• Hazardous Substances Data: 13741-90-7(Hazardous Substances Data)

Usage

General Description

2,4,6-triaminoquinazoline is a chemical compound with the formula C9H7N5. It is a yellow crystalline solid with a molecular weight of 185.19 g/mol. 2,4,6-triaminoquinazoline is used in the pharmaceutical industry as a building block for the synthesis of various drug molecules. It has also been studied for its potential antitumor and antimalarial properties. As a triamino derivative of quinazoline, it exhibits unique properties that make it suitable for various scientific and industrial applications. Its structure and reactivity make it a valuable tool for medicinal chemistry and drug development.

InChI:InChI=1/C8H9N5/c9-4-1-2-6-5(3-4)7(10)13-8(11)12-6/h1-3H,9H2,(H4,10,11,12,13)

Upstream product

• 113494-59-0 2,2',4,4'-tetra-amino-6,6'-azoquinazoline 
• 113494-57-8 2,4-diamino-6-azidoquinazoline 
• 7154-34-9 2,4-diamino-6-nitroquinazoline 
• 16588-02-6 4-chloro-3-cyanonitrobenzene 
• 17420-30-3 5-nitroanthranilonitrile 

Downstream Products

• 88050-31-1 di-tert-butyl-5,8-dideazaisoaminopterin 
• 132131-20-5 2,4-diamino-6-iodoquinazoline 
• 18917-68-5 2,4-diamino-6-quinazoline-6-carbonitrile 
• 122246-40-6 N⁶-[1-(3,4,5-Trimethoxy-phenyl)-meth-(E)-ylidene]-quinazoline-2,4,6-triamine 
• 27023-77-4 2,4-diamino-quinazoline-6-carboxaldehyde 
• 213338-84-2 N⁶-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine 
• 118291-97-7 N⁶-(2,4-dimethoxy-benzyl)-quinazoline-2,4,6-triamine 
• 213338-85-3 N⁶-(3,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine 
• 213338-88-6 N⁶-(2,3,4-trimethoxy-benzyl)-quinazoline-2,4,6-triamine 
• 13794-53-1 N⁶-benzylquinazoline-2,4,6-triamine 
• 13794-67-7 N⁶-(3,4,5-trimethoxy-benzyl)-quinazoline-2,4,6-triamine 
• 207562-23-0 2,4-diaminoquinazoline-6-carboxylic acid 

Relevant articles and documents

Photoswitchable Antimetabolite for Targeted Photoactivated Chemotherapy

The efficacy and tolerability of systemically administered anticancer agents are limited by their off-target effects. Precise spatiotemporal control over their cytotoxic activity would allow improving chemotherapy treatments, and light-regulated drugs are well suited to this purpose. We have developed phototrexate, the first photoswitchable inhibitor of the human dihydrofolate reductase (DHFR), as a photochromic analogue of methotrexate, a widely prescribed chemotherapeutic drug to treat cancer and psoriasis. Quantification of the light-regulated DHFR enzymatic activity, cell proliferation, and in vivo effects in zebrafish show that phototrexate behaves as a potent antifolate in its photoactivated cis configuration and that it is nearly inactive in its dark-relaxed trans form. Thus, phototrexate constitutes a proof-of-concept to design light-regulated cytotoxic small molecules and a step forward to develop targeted anticancer photochemotherapies with localized efficacy and reduced adverse effects.

PHOTORESPONSIVE COMPOUND

PROBLEM TO BE SOLVED: To provide a novel photoresponsive compound that is useful as a medicament, or a reagent for analyzing in vivo intermolecular interaction, or the like. SOLUTION: Provided is a compound represented by the following formula (I-1) or (I

Design, synthesis and cytotoxic evaluation of quinazoline-2,4,6-triamine and 2,6-diaminoquinazolin-4(3H)-one derivatives

A series of quinazoline-2,4,6-triamine (quinazoline) and 2,6-diaminoquinazolin-4(3H)-one (quinazolinone) derivatives were designed, synthesized and evaluated as cytotoxic agents in three cancer cell lines (HCT-15, SKOV-3, and MDA-MB-231) using conventiona